C4 Therapeutics Stock Alpha and Beta Analysis
| CCCC Stock | USD 4.05 0.10 2.41% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as C4 Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in C4 Therapeutics over a specified time horizon. Remember, high C4 Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to C4 Therapeutics' market risk premium analysis include:
Beta 0.3 | Alpha (0.52) | Risk 4.93 | Sharpe Ratio (0.15) | Expected Return (0.73) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
CCCC |
C4 Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. C4 Therapeutics market risk premium is the additional return an investor will receive from holding C4 Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in C4 Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate C4 Therapeutics' performance over market.| α | -0.52 | β | 0.30 |
C4 Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of C4 Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how C4 Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.C4 Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how C4 Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading C4 Therapeutics shares will generate the highest return on investment. By understating and applying C4 Therapeutics stock market price indicators, traders can identify C4 Therapeutics position entry and exit signals to maximize returns.
C4 Therapeutics Return and Market Media
The median price of C4 Therapeutics for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 6.01 with a coefficient of variation of 10.83. The daily time series for the period is distributed with a sample standard deviation of 0.64, arithmetic mean of 5.87, and mean deviation of 0.48. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 2250 shares by Siegel Jolie of C4 Therapeutics subject to Rule 16b-3 | 09/16/2024 |
2 | Disposition of 661 shares by Boyle Scott N of C4 Therapeutics at 6.36 subject to Rule 16b-3 | 09/17/2024 |
3 | Disposition of 1837 shares by Kendra Adams of C4 Therapeutics at 6.38 subject to Rule 16b-3 | 09/18/2024 |
4 | Acquisition by Anderson Kenneth Carl of 2023 shares of C4 Therapeutics at 5.56 subject to Rule 16b-3 | 10/01/2024 |
5 | Crypto Content Creator Campus onthult gerenommeerde sprekers voor eerste evenement | 10/11/2024 |
6 | Crypto Content Creator Campus prsentiert hochkartige Referenten fr die Erffnungsveranstaltung | 10/14/2024 |
7 | Insider Trading | 10/21/2024 |
8 | Acquisition by Mahaney Paige of 345600 shares of C4 Therapeutics at 6.0 subject to Rule 16b-3 | 10/29/2024 |
9 | C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 10/31/2024 |
10 | PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer | 11/05/2024 |
11 | Disposition of 12500 shares by Andrew Hirsch of C4 Therapeutics subject to Rule 16b-3 | 11/07/2024 |
12 | C4 Therapeutics, Inc.s 33 percent Share Price Plunge Could Signal Some Risk | 11/15/2024 |
13 | Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc | 11/20/2024 |
About C4 Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including CCCC or other stocks. Alpha measures the amount that position in C4 Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 18.86 | 18.57 | 17.26 | 11.72 | Receivables Turnover | 8.01 | 21.11 | 1.76 | 1.67 |
C4 Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of C4 Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, C4 Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of C4 Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of C4 Therapeutics. Please utilize our Beneish M Score to check the likelihood of C4 Therapeutics' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with C4 Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out C4 Therapeutics Backtesting, C4 Therapeutics Valuation, C4 Therapeutics Correlation, C4 Therapeutics Hype Analysis, C4 Therapeutics Volatility, C4 Therapeutics History and analyze C4 Therapeutics Performance. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
C4 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.